LeMaitre Vascular, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- George W. LeMaitre
- Full Time Employees
- 651
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 63 Second Avenue Burlington MA United States of America 01803
- IPO Date
- Oct 19, 2006
- CIK
- 0001158895
- Website
- lemaitre.com
- Similar Companies
- Business
- LeMaitre Vascular, Inc. develops, manufactures, and markets disposable and implantable medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease worldwide. The company offers a diversified portfolio of products including valvulotomes to disrupt valves in saphenous veins for arterial bypass; embolectomy and thrombectomy catheters to remove arterial and venous clots; occlusion and perfusion catheters to control and deliver blood flow; carotid shunts to maintain cerebral blood flow during surgery; vascular grafts such as LifeSpan expanded polytetrafluoroethylene grafts, biosynthetic grafts for lower extremity bypass and dialysis access, and Artegraft bovine carotid artery biologic grafts; biologic patches including XenoSure, VascuCel, and CardioCel for vessel and cardiac repair; allografts for vascular reconstruction and cryopreservation services; phlebectomy systems for varicose vein treatment; angioscopes for vessel visualization; radiopaque tape; and vessel closure systems using titanium clips. LeMaitre Vascular sells directly to hospitals in over 25 countries across North America, Europe, the Middle East, Africa, and Asia-Pacific through more than 160 sales representatives and distributors in 90 countries; it was founded in 1983 and is headquartered in Burlington, Massachusetts. Recent developments include strong organic sales growth of 15% in 2025 with raised full-year revenue guidance to $251 million, driven by 27% expansion in catheters and grafts and 23% growth in EMEA; receipt of MDR CE Mark approval for Artegraft enabling accelerated European market penetration for EVAR applications; a 26% surge in Q4 2024 operating income from Artegraft integration and operational efficiencies boosting gross margins to 70%; and a 25% increase in quarterly dividend to $0.20 per share in early 2025.
Company News
PAHC or LMAT: Which Is the Better Value Stock Right Now?
LeMaitre to Participate at Upcoming Investor Conferences in September
Dividend Champion, Contender, And Challenger Highlights: Week August 16
GEHC or LMAT: Which Is the Better Value Stock Right Now?
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular Q2 Earnings Call Highlights
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
LeMaitre Q2 2026 Financial Results
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
We Have A Valuation Problem - May Dividend Income Report
Casey's & 3 More Stocks With Strong Interest Coverage to Buy Now
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre to Participate at Upcoming Investor Conferences in June
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre to Present at the Bank of America Healthcare Conference
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) Upgraded to Buy: Here's Why
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript